From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

WIB_icon

Number of Older Patients Receiving AlloHCT Increased Over the Past Decade

Historically, older adults have not been considered optimal candidates for hematopoietic cell transplantation (HCT) because of concerns about transplant-related toxicity and mortality. Over the...
WIB_icon

Examining Nilotinib to Prevent Post-Transplant Relapse in Patients With Ph+ Leukemia

In previous research published in Blood, Paul A. Carpenter, MBBS, from the Fred Hutchinson Cancer Research Center in Seattle, Washington, and co-authors determined that...
WIB_icon

For Lenalidomide-Refractory Myeloma, Pomalidomide Is a Safe, Effective Secondline Option

While it has become a standard to include lenalidomide in the frontline treatment of patients with multiple myeloma (MM), most patients have disease that...

Managing Toxicities of Dasatinib in Patients With CP-CML

In randomized studies, the second-generation tyrosine kinase inhibitor dasatinib demonstrated deeper and more rapid major molecular responses (MRs) in patients with newly diagnosed chronic-phase...
WIB_icon

Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL

Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...
WIB_icon

Managing GVHD Following HCT: New Uses for Old Treatments?

Graft-versus-host disease (GVHD) remains a major complication following allogeneic hematopoietic cell transplantation (alloHCT) and, when severe, is associated with poor long-term overall survival. Two...

Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL

Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...
WIB_icon

Population-Based Study Finds Persistent Gaps in Understanding and Identification of VTE Risk

An estimated 500,000 venous thromboembolism (VTE) events occur annually in the United States, about half of which are related to current or recent hospitalizations,...
WIB_icon

Isatuximab Plus Lenalidomide and Dexamethasone Active in Relapsed/Refractory Multiple Myeloma

Treatment with the investigational anti-CD38 monoclonal antibody isatuximab (in combination with lenalidomide and dexamethasone) led to an overall response rate (ORR) of 51 percent...

Are HCT Patients in Brazil at Increased Risk of Zika and Other Mosquito-Transmitted Infections?

Since 2015, Brazil has experienced a triple epidemic of dengue, chikungunya, and Zika infections, putting the more than 2,000 hematopoietic cell transplantation (HCT) recipients...
Advertisement

Current Issue

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.